Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations
- PMID: 37656059
- DOI: 10.1158/1078-0432.CCR-23-1700
Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations
Abstract
Trastuzumab deruxtecan (T-DXd) is reshaping the therapeutic landscape of HER2-positive tumors. A recent article reports on the preclinical activity of the combination of T-DXd plus adavosertib, WEE1 kinase inhibitor, which promises to expand the use of this antibody-drug conjugate in HER2-positive tumors with CCNE1 coamplification. See related article by DiPeri et al., p. 4385.
©2023 American Association for Cancer Research.
Comment on
-
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.Clin Cancer Res. 2023 Nov 1;29(21):4385-4398. doi: 10.1158/1078-0432.CCR-23-0103. Clin Cancer Res. 2023. PMID: 37279095 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
